FIELD: biotechnology.
SUBSTANCE: invention presents: an antibody against human Fn14 or its antigen-binding fragment and its use for the production of a pharmaceutical composition for the prevention or treatment of cancerous cachexia, polynucleotides encoding a variable region of heavy and light chains of the antibody against human Fn14, an expression vector, host cells, and methods for the production of an antibody against Fn14. In addition, pharmaceutical compositions for suppression of inflammation by inhibition of activation of human Fn14, a method for the prevention or treatment of cancerous cachexia, as well as pharmaceutical compositions for the prevention or treatment of cancer or cancerous cachexia are presented.
EFFECT: invention allows for the production of an antibody against human Fn14, which binds to human Fn14 for inhibition of its action, thereby preventing or treatment of cachexia of cancer patients.
30 cl, 7 dwg, 3 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
| MONOCLONAL ANTIBODY AGAINST FZD10, ITS USE | 2017 |
|
RU2765431C2 |
| MONOCLONAL ANTIBODY AGAINST MELK AND ITS USE | 2017 |
|
RU2756982C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMORS | 2017 |
|
RU2755894C2 |
| IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
| BISPECIFIC ANTIBODY | 2019 |
|
RU2796019C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
